

Available online on 15.08.2021 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-20, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

A Review Article on Proniosome: As A Drug Carrier

Dr. Anupam Kr. Sachan, Sunil Kumar, Tapasya Dwivedi*

Dayanand Dinanath College, Institute of Pharmacy, Kanpur, India

ABSTRACT

A drug carrier is any substrate used in the process of drug delivery.

The basic component of the drug delivery system is an appropriate drug carrier that sets out to improve the selectivity, effectiveness, and safety of drug administration. So, based on their biocompatible, biodegradable, and non-immunogenic structure, Proniosomes are promising drug carriers that are non-ionic surfactant-based multilamellar or unilamellar vesicle are now widely used as an alternative to the liposome. On the basis of structure, they are similar to liposomes in having bilayer but having chemical differences in monomer units which make Proniosomes stable. They can entrap both hydrophilic and lipophilic drugs of using either in an aqueous layer or in the vesicular membrane. Proniosomal carriers are suitable for the transdermal delivery of numerous pharmacological agents, including antioxidant, anticancer, anti-inflammatory, antimicrobial, and antibacterial molecules.

Keywords: Proniosome, Advantage, Application, Methodology, Drug carrier

ARTICLE INFO: Received 26 June 2021; Review Complete; 03 August 2021 Accepted; 11 August 2021 Available online 15 August 2021



Cite this article as:

Sachan AK, Kumar S, Dwivedi T, A Review Article on Proniosome: As A Drug Carrier ., Asian Journal of Pharmaceutical Research and Development. 2021; 9(4):128-131. DOI: <http://dx.doi.org/10.22270/ajprd.v9i41010>

*Address for Correspondence:

Tapasya Dwivedi, Dayanand Dinanath College, Institute of Pharmacy, Kanpur, India

INTRODUCTION:

This review provides a brief overview of using proniosome as a drug carrier by explaining its structure, advantage, application, and mode of action in the targeted site of the body. Colloidal particulate structures such as proniosome as drug delivery systems have distinct advantages over conventional dosage forms. These carriers can act as drug reservoirs and are primarily used to control the release of a drug into systemic circulation. This can be fulfilled either by slow release of drug over a long period of time or by activating release at the drug's target by stimulus, such as a change in pH and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability of many drugs with poor water solubility with poor solubility and membrane permeability.

Proniosomes are used as a drug carrier because they have benefits such as low cost, ease to formulate, good stability. They are much more stable because their forming materials are more stable than those of lipids both in terms of physical and chemical stability.

History of Proniosomes:

Nearly 25 odd years of continual and detailed research to reach the highest, the first formulation to be licensed for use in human beings is Liposome. However, liposomes have limited success in terms of oral delivery and suffer from physicochemical stability problems such as sedimentation, aggregation, fusion, phospholipid hydrolysis, and/or oxidation. To resolve these stability issues, proliposome approach has provided a major advancement by using the dry, free-flowing product, which is more stable during sterilization and storage²⁶.

Proliposome is the dry, free-flowing powder formulations containing water-soluble carrier particles coated with phospholipids which, upon the addition of water, disperse to form a multilamellar liposomal suspension. Despite these merits, proliposome preparation involves technical difficulties like usage of vacuum or nitrogen atmosphere during preparation and storage to prevent oxidation of phospholipids^{3,4}.

Niosomes are better alternatives to liposomes as promising drug carriers with greater chemical stability, entrapment efficiency of both hydrophobic and hydrophilic drugs and are less toxic due to their non-ionic nature. However, like liposomes, niosomes also have physical stability problems such as leakage, fusion, aggregation, and sedimentation²⁷. These problems can be evaded by proniosomes²⁵.

Proniosomes are dry, free-flowing formulations of the surfactant-coated carrier, which can be rehydrated by brief agitation in hot water to form a multi-lamellar niosome suspension suitable for administration by oral or other routes^{29,30}.

Definition of Proniosome:

Proniosomes are the dry formulation of water-soluble carrier particles that are coated with a surfactant. They are rehydrated to form niosomal dispersion immediately before use on agitation in hot aqueous media within minutes. Proniosomes are physically stable during storage and transport.

Advantages of proniosomes:

- Improvement in bioavailability and permeation of the drug.
- Enhances the skin permeation and develops a transdermal therapeutic system.
- Ease of manufacture and scale-up process.
- Avoid stability-related issues such as – aggregation, fusion, and sedimentation.
- Used for targeted drug delivery of drugs.
- Fewer adverse drug reactions.

Structure of Proniosome:

Proniosomes are microscopic lamellar structures.

The structural components present in proniosome are-

- Cholesterol (a steroid derivative, which is used to provide rigidity and proper shape, conformation to proniosome form)
- Non-ionic surfactant
- Drug
- Solvents, such as – ethanol, propanol, butanol, isopropanol, phosphate buffer, and glycol, etc.
- Carrier materials, such as – mannitol, spray-dried lactose, maltodextrin, sorbitol, etc.
- Charge inducing molecule

The non-ionic surfactants used for the preparation of proniosome are-

- The alkyl or Dialkyl polyglycerol
- Alkyl or Dialkyl ethers
- Span (64, 20, 85, 80)
- Tween (20, 40, 60,80)
- Brij (35, 73, 92, 95)

Types of Proniosomes:

Dry granular proniosomes-

1. Sorbitol based proniosomes
2. Maltodextrin based proniosomes

Sorbitol-based proniosomes is a dry formulation that involves sorbitol as a carrier, which is further coated with non-ionic surfactant and is used as a niosome within minutes by the addition of hot water followed by agitation.

Maltodextrin-based proniosomes are prepared by the fast slurry method. The surface of the proniosome is increased by the use of hollow maltodextrin particles which leads to a thinner surfactant coating that is suitable for rehydration.

Liquid crystalline proniosomes-

This type of proniosomes are reservoirs for transdermal delivery of the drug. The transdermal patch involves aluminum foil as a baking material along with a plastic sheet. Proniosomal gel is spread evenly on the circular plastic sheet followed by covering with a nylon mesh.

Proniosome as a drug carrier:

Proniosomes are very promising carriers for the delivery of numerous pharmacological and diagnostic agents. A number of publications have reported the preparation, characterization, and use of proniosomes as drug carriers. Because of their non-ionic nature, they offer excellent biocompatibility and low toxicity. The unique structure of proniosomes allows the development of effective novel drug delivery systems with the ability to load both hydrophilic and lipophilic drugs. Hydrophilic drugs and lipophilic drugs are entrapped into the aqueous core and membrane bilayer of the proniosome respectively. Proniosomes have also been used as carriers for iobitridol, a diagnostic agent used for X-ray imaging. Topical proniosomes may serve as solubilization matrix, as a local depot for sustained release of dermally active compounds, as penetration enhancers, or as rate-limiting membrane barrier for the modulation of systemic absorption of drugs.

Methods of preparation:

Proniosomes can be prepared by following methods: -

- a. Slurry method
- b. Coacervation phase separation method
- c. The slow spray coating method

Slurry method –

Proniosomes can be prepared by using a solution of cholesterol and surfactants. The non-ionic surfactants used are – span and Brij. The coating carrier used is maltodextrin. The drug and stock solution was added to a 100 ml round bottom flask containing 500 mg of maltodextrin carrier. Then chloroform: menthol solution is added to form a slurry. The flask is attached to a rotary evaporator for the evaporation of the solvent and it is rotated at 60-70rpm, temperature maintained at 45°C and a reduced pressure of 600 mmHg. The process is continuing until the mass in the flask had become a dry free-flowing product. These materials are further dried overnight in a desiccator under a vacuum at room temperature. The dry preparation is referred to as proniosome powder.


Coacervation phase separation method –

This method is used for the preparation of proniosomal gel. All the required materials, such as – surfactants, carriers, cholesterol are taken in a dry and clean wide-mouth glass

container and to this, the solvent should be added to it. Then the container is sealed with aluminum foil and placed in a water bath 60-70°C until all the materials get dissolved. After that cool the preparation at room temperature until it is converted into proniosomal gel.

Slow spray coating method –

A 100 ml round bottom flask containing the desired amount of carrier can be attached to a rotary evaporator. The



Evaluation parameters in Proniosome:

Particle size and shape analysis: The particle sizedetermination of proniosome powder was carried out using an optical microscope along with a stage micrometer having an accuracy of 0.01 nm. The average of a powder was calculated using the following formula: -

$$[X = \frac{E(Xi)}{N}]$$

The angle of repose: The angle of repose is the angle formed by the horizontal base of the bench surface and the edge of a cone-like pile of granules. It can be calculated as: -

$$[\Theta = \tan^{-1} (h/r)]$$

Drug Entrapment Efficiency: The entrapped drugproniosome was determined by exhaustive dialysis method or by centrifugation method. The entrapment efficiency of the drug was calculated by using the following equation –

Amount of drug entrapped

$$[\% \text{ Entrapment Efficiency} = \frac{\text{The amount of drug}}{\text{The total amount of drug}} \times 100]$$

In-Vitro Drug Release: In-vitro release pattern of proniosomes suspension was carried out by dialysis bag method. A dialysis sac was washed and soaked in distilled water. The vesicle suspension was pipette into a bag made up of tubing and sealed followed by placing the dialysis bag into a beaker containing 200 mL of PBS pH 7.4. The vessel was placed over a magnetic stirrer (50 rpm) and the

evaporator has to be evacuated and the rotating flask can be rotated in a water bath under vacuum at 65-70°C for 15-20 min. This process is repeated until all of the surfactant solutions have been applied. The evaporation should be continued until the powder becomes completely dry.

temperature was maintained at 37°C ± 0.5°C. Samples were withdrawn at predetermined time intervals and immediately replaced with the fresh medium to maintain the sink condition throughout the experiment. Samples were diluted and analyzed for drug content by using a UV/visible spectrophotometer at 265 nm.

Stability study: Stability study is a routine method performed on drug substances and products and employed at various stages of product development. To study the diffusion of the drug from Proniosome, a drug release study was carried out. Stability of proniosomal dispersion was carried out for 30days at 2-80°C and Room temperature. The response obtained for different parameters proniosomal dispersion during the stability period.

Application of Proniosome:

Proniosome in gene delivery - Some non-viral vectors found as an alternative to viral gene delivery systems. Among non-viral vectors, proniosomes could also potentially serve as gene delivery systems because it has shown favourable properties for gene delivery such as -low cost, easy to formulate, good stability, easy production, and less toxic due to presence of non-ionic surfactant.

Drug targeting - One of the most useful aspects of proniosome is its ability to target drugs. The efficiency and specificity of cellular targeting of niosomal drug delivery systems can be further improved by active targeting for tumor therapy, by using a ligand coupled to the surface of niosomes, which could be actively taken up. proniosomes can be used to target drugs to the reticuloendothelial system. The reticuloendothelial system (RES) preferentially

takes up proniosome vesicles. Proniosomes can also be utilized for targeting drugs to organs other than the RES. A carrier system (such as antibodies) can be attached to proniosomes (as immunoglobulin's bind readily to the lipid surface of the proniosome) to target them to specific organs.

Anticancer drug delivery - The therapeutic efficacy of many anticancer drugs is limited by their poor penetration into tumor tissue and by their severe side effects on healthy cells. Various attempts have been made to overcome these drawbacks, including the use of proniosomes as a novel drug delivery system. Proniosomes can alter the metabolism; prolong circulation and half-life of the drug, thus decreasing the side effects of the drugs. Proniosomes are decreased rate of proliferation of tumors and higher plasma levels accompanied by slower elimination.

Delivery of Antibiotics and Anti-inflammatory agents -

Proniosomal carriers are also suitable for the delivery of antibiotics and anti-inflammatory agents. These carriers have been used extensively to improve poor skin penetration and as well as enhance skin retention of the drugs. A goal of topical delivery is that the drug is transported through the stratum corneum, thereby effectively reaching the target tissue. The proniosomal gel developed by Jacob et al. demonstrated successful delivery of acyclovir through topical administration.

CONCLUSION:

Recent advancements in the field of scientific research have resulted that proniosomes are used as a drug carrier for better targeting of the drug at aspecific tissue destination because they are made up of non-ionic surfactant, so less toxic and have an opportunity of loading hydrophilic, lipophilic drugs or both drugs together. The relevant studies demonstrated that proniosomes improve the stability of the entrapped drug, reduce the dose, and enable targeted delivery to a specific type of tissue.

REFERENCE:

- Rita B, Lakshmi PK. Preparation and Evaluation of Modified Proniosomal Gel. *Journal of Applied Pharmaceutical Science*, 2012; 2(5); 85-91.
- Pal P; Dr. Mishra S. Formulation and Development of Antifungal Proniosomal Gel for Topical Application. *World Journal of Pharmaceutical Research*, 2017; 6(5): 656-674.
- Katare O, Vyas S, Dixit V. Effervescent granule based proliposome of Ibuprofen. *Journal of Microencapsulation*, 1990; 7(4): 455-62.
- Payne N, Browning I, Hynes, C. Characterization of proliposome. *Journal of Pharmaceutical Science*, 1986; 75(4): 330 – 333.
- Dr. Mangilal T. T., Patnik KSK, Kumar SM, Thirupati L, Nagaraju I. Preparation and Evaluation of Proniosomal Rosuvastatin Gel for Transdermal Delivery. *World Journal of Pharmaceutical Research*, 2015; 4(6): 2309-2322.
- Nimbalwar M, Upadhyay K and Dixit G. Fabrication and Evaluation of Antihistaminic Activity of Proniosome Bases Transdermal Patches. *Pharmacophore-A International Research Journal*, 2016; 7(2): 82-95.
- Hardia Aarti, Jamindar D, Mahajan A, Hardia A. Formulation and In-vitro and Skin Permeability Evaluation of Dexamethasone Loaded Niosomal Gel. *Asian Journal of Pharmaceutical Research and Development*, 2017; 5(2): 01-09.
- Vardhani CHS, Niraosha M, Chandrasekhar K.B. Proniosomal Gel – An Effective Approach for Topical and Transdermal Drug Delivery. *International Journal of Research and Pharmaceutical Science*, 2016; 7(2): 179-188.
- Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. Design and Development of a Proniosomal Transdermal Drug Delivery System. *Tropical Journal of Pharmaceutical Research*, 2007; 6(2): 687-693.
- Sagar S, Lavanya S, Sagar V, Dr. Nanjwade BK. Indo American Journal of Pharmaceutical Sciences. *Indo American Journal of Pharmaceutical Sciences*, 2017; 4(8): 2513-2520.
- Sengodan T, Biradar S, Rathi V, Rathi JC. Formulation and Evaluation of Maltodextrin. *Journal of Pharmatech Research*, 2009; 1(3): 517-523.
- Sulthana AA, George BJ, Samuel J. *International Journal of Pharmaceutical, Chemical, and Biological Science*, 2015; 5(4): 879-882.
- Pandit P. G, Parakh D. R, Patil M. P. Proniosomal Gel for improved Transdermal Drug Delivery: An Overview. *World Journal of Pharmaceutical Research*, 2015; 4(8): 560-586.
- Ramakanth S, Chetty M. C, Sudhakar Y, Thiruvengadrajana V. S, Amitha P, Gopinath C. Development and In-vivo Evaluation of Proniosomal Based Transdermal Delivery System of Atenolol. *Future Journal of Pharmaceutical Science*, 2018; 4(3): 80-87.
- Kumar K, Rai AK. Development and Evaluation of Proniosome Encapsulated Curcumin for Transdermal Administration. *Tropical Journal of Pharmaceutical Research*, 2011; 10(6): 697-703.
- Soujanya C, Prakash R. P. Formulation and Evaluation of Proniosomal Gel Based Transdermal Delivery of Atorvastatin Calcium by Box-Behnken Design. *Asian Journal of Pharmaceutical and Clinical Research*, 2019; 12(4): 335-43.
- Munish A, Kamal S. Proniosomes Formulations Using Maltodextrin and Mannitol as Carriers. *International Journal of Pharmaceutical and Chemical sciences*, 2014; 3(2): 547-551.
- Sivaprasad S. N. D, Lakshman P. K, Srinivas M, B. Brahmaiah, Sreekanth Nama. Proniosome: A Novel Approach to Vesicular Drug Delivery System. *International Journal of Innovative Drug Discovery*, 2013; 3(2): 85-90.
- Shehata T. M, Ibrahim M. M, Elsewedy H. S. Curcumin Niosomes Prepared from Proniosomal Gels: In-vitro Skin Permeability, Kinetic and In-vivo Studies. *Polymers*, 2021; 13: 1-14.
- Bhama S, Sambath R. K. Development and Evaluation of Letrozole Loaded Proniosomes as Drug delivery System. *International journal of Research in Pharmaceutical Sciences*, 2016; 6(4): 363-368.
- Kumar Sunil, Jain P. K, Pandey N, Saxena G. Comparative Study of Proniosomal Drug Delivery System of Flurbiprofen. *Journal of Chemical and Pharmaceutical Research*, 2016; 8(5): 222-228.
- Dr. Deepu S, Dr. Kurichan M. A, Sreekavya B. Formulation and Evaluation of Antihistaminic Activity of Proniosome Based Transdermal Patches. *International Journal Research and Review*, 2018; 5(10): 177-188.
- Boddy M, Choppri V, Vamshi R. K, Badam M. Formulation and Evaluation of Proniosome of Felodipine. *Drug Des, an open access journal*, 2017; 6(3): 1-9.
- Sammour R. M. F, Taher M, Chatterjee B, Shahiwala A, Mahmood S. Optimization of Aceclofenac Proniosomes by Using Different Carriers. *MDPI- Pharmaceutics*, 2019; 350(11): 1-19.
- Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. *International J Pharm*, 1999; 206(1-2): 23–35.
- Raju J, Karthik YJ, Ashok V, et al. Bioavailability enhancement of zaleplon via proliposome: Role of surface charge. *European Journal of Pharm BioPharma*, 2012; 80: 347–57.
- Srikanth, Kumar A. Y, Setty M. C. Formulation and Evaluation of Maltodextrin Bases Doxorubicin HCl Proniosomes. *Research Journal Pharm and Tech*, 2019; 12(6):
- Dhangar R. K, Mishra S. S, Pathak A, Raghuvanshi N, Yagnik S. K, Dubey A, Rawat D. Formulation and Evaluation of Proniosomal Gel in Ocular Drug. *Current Research in Pharmaceutical Science*, 2012; 5(2): 42-47.
- Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-Behnken design. *AAPS Pharm Sci Tech* 2007; 8(4): 1–7.
- KUMAR A, Parthiban S, and Kumar G. P. S. *European Journal of Biomedical and Pharmaceutical Sciences*, 2016; 3(5): 362-374.
- Jampala R, Radha GY, Trideva SK, Burada S. *Asian Journal of Pharmaceutical, and Clinical Research*, 2019; 12(1): 54-61.
- Mokhtar M, Sammour OA, Hammad MA, et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. *Int J Pharm*, 2008; 361(1-2):104–11.